The results of the phase III TROPION‐Breast01 study will help define the role of Dato‐DXd in the metastatic HR+/HER2‐ breast cancer setting in patients who have progressed on, or are ineligible for, endocrine therapy and after chemotherapy. Here, ERBB2 is linked to breast carcinoma.